XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
  Diabetes
   Insulin Resistance
   NIDDM
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate
Search

Last Updated: Nov 18, 2006 - 1:55:25 PM

NIDDM Channel
subscribe to NIDDM newsletter

Latest Research : Endocrinology : Diabetes : NIDDM

   DISCUSS   |   EMAIL   |   PRINT
TORC2 - Key regulator of blood glucose levels discovered
Sep 10, 2005 - 11:14:00 PM, Reviewed by: Dr.

�It is very exciting to understand how glucose production in the liver is regulated. Now, we can try to improve the way how type 2 diabetics handle blood sugar.�

 
In many patients with type 2 diabetes, the liver acts like a sugar factory on overtime, churning out glucose throughout the day, even when blood sugar levels are high. Scientists at the Salk Institute for Biological Studies discovered a key cellular switch that controls glucose production in liver cells.

This switch may be a potential new target for the development of highly specific diabetes drugs that signal the liver to reduce the production of sugar. The Salk researchers, led by Marc Montminy, a professor in the Clayton Foundation Laboratories for Peptide Biology, published their findings in the Sept. 7th online issue of Nature.

�It is very exciting to understand how glucose production in the liver is regulated. Now, we can try to improve the way how type 2 diabetics handle blood sugar,� says Montminy.

The newly discovered switch, a protein named TORC2, turns on the expression of genes necessary for glucose production in liver cells.

When describing glucose�s role in health and disease, Montminy compares the human body to a hybrid car that runs on a mix of fuels depending on its activity status: gas, or glucose, is used for high-energy activities, and battery power, or body fat, for low-energy activities. During the day, when food refuels the �gas tank,� the body burns mainly glucose, and during sleep, it burns primarily fat.

The body switches from glucose to fat burning mainly in response to two key hormones -- insulin and glucagon -- that are produced by the pancreas. During feeding, the pancreas releases insulin, which promotes the burning of glucose. At night, however, the pancreas releases glucagon into the bloodstream, which signals the body to fire up the fat burner.

But even during sleep, our brain needs a constant supply of glucose to function properly. For that reason, our body actually manufactures glucose during sleep or when we are fasting. That process, called gluconeogenesis, is carried out mainly in the liver.

Insulin normally shuts down the ability of the liver to produce glucose. In individuals with Type II diabetes, however, insulin is unable to inhibit sugar production in the liver, �either because the pancreas is not producing enough insulin or because insulin�s signal can�t be �heard,�� says Montminy. When the liver is unable to hear the insulin signal, excess glucose builds up in the bloodstream.

In addition to so-called insulin sensitizing drugs that allow insulin to work better, researchers are looking for alternative ways to shut down the production of glucose in the liver of diabetics. �Figuring out how to control glucose production in the liver is critical because many complications of diabetes, such as heart disease, kidney failure and blindness, can be reduced by maintaining a very tight control over blood sugar levels,� he says.

As glucose levels run low during fasting, the pancreas sends out the hormone glucagon and instructs the liver to produce glucose. This increase in glucagon turns on the TORC2 switch and allows the liver to make more glucose. Mice that were genetically modified to make more or less TORC2 produced more or less glucose depending on the amount of available TORC2 (transducer of regulated CREB activity).

Most of the time, TORC2 sits in the cellular compartment that surrounds the nucleus, where all the genes are located. When a glucagon signal arrives, the TORC2 switch crosses the nuclear membrane, teams up with the transcriptional activator CREB and turns on all the genes necessary for gluconeogenesis. �Being located in a different part of the cell is what keeps the TORC2 switch off,� explains Montminy.

The researchers also discovered that a chemical modification on TORC2 itself sequesters the protein in the cytoplasm, the viscous substance inside the cell that surrounds the nucleus. �Since we now know the molecular mechanism by which TORC2 is inactivated we can start looking for small molecules that do the same thing,� says Montminy.
 

- Sept. 7th online issue of Nature
 

www.salk.edu

 
Subscribe to NIDDM Newsletter
E-mail Address:

 

The Salk Institute for Biological Studies in La Jolla, California, is an independent nonprofit organization dedicated to fundamental discoveries in the life sciences, the improvement of human health and the training of future generations of researchers. Jonas Salk, M.D., whose polio vaccine all but eradicated the crippling disease poliomyelitis in 1955, opened the Institute in 1965 with a gift of land from the City of San Diego and the financial support of the March of Dimes.

Related NIDDM News
Data support role for adult spleen cells in regeneration of beta cells
Researchers reveal mechanisms behind Thiazolidinediones in type 2 diabetes
High-fat diet supresses GnT-4a activity to cause type 2 diabetes
Low blood glucose levels may complicate gastric bypass surgery
Muraglitazar found to increase adverse cardiovascular events
Insulin's role in blocking release of energy
TORC2 - Key regulator of blood glucose levels discovered
Panel Recommends Muraglitazar for the Treatment of Type 2 Diabetes
Persons at risk for type 2 diabetes have lower rate of cellular energy production
Sirt1 protein enhances the secretion of Insulin


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us